PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product NSAIDs - Market size and forecast 2018-2023 Colchicine - Market size and forecast 2018-2023 Others - Market size and forecast 2018-2023 Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors AstraZeneca Plc Bayer AG Johnson & Johnson Services Inc. Pfizer Inc. Takeda Pharmaceutical Co. Ltd. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global cardiovascular disorder treatment market Exhibit 02: Segments of global cardiovascular disorder treatment market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Emerging trends in global pericarditis drugs market Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Market overview 2018 Exhibit 10: Analysis of global pericarditis drugs market 2018 Exhibit 11: Global market: Year-over-year growth 2019-2023 (%) Exhibit 12: Five forces analysis 2018 Exhibit 13: Five forces analysis 2023 Exhibit 14: Bargaining power of buyers Exhibit 15: Bargaining power of suppliers Exhibit 16: Threat of new entrants Exhibit 17: Threat of substitutes Exhibit 18: Threat of rivalry Exhibit 19: Market condition - Five forces 2018 Exhibit 20: Product - Market share 2018-2023 (%) Exhibit 21: Comparison by product Exhibit 22: NSAIDs - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Treatment regime with NSAIDS for pericarditis Exhibit 24: NSAIDs - Year-over-year growth 2019-2023 (%) Exhibit 25: Colchicine - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Colchicine - Year-over-year growth 2019-2023 (%) Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 28: Others - Year-over-year growth 2019-2023 (%) Exhibit 29: Market opportunity by product Exhibit 30: Customer landscape Exhibit 31: Market share by geography 2018-2023 (%) Exhibit 32: Geographic comparison Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Centers for Disease Control and Prevention (CDC) facts about heart disease Exhibit 35: North America - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in North America Exhibit 37: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 38: Europe - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in Europe Exhibit 40: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 41: Asia - Year-over-year growth 2019-2023 (%) Exhibit 42: Top 3 countries in Asia Exhibit 43: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 44: ROW - Year-over-year growth 2019-2023 (%) Exhibit 45: Top 3 countries in ROW Exhibit 46: Key leading countries Exhibit 47: Market opportunity Exhibit 48: Side effects associated with use of NSAIDs Exhibit 49: Renal impairment associated with use of NSAIDs Exhibit 50: Impact of drivers and challenges Exhibit 51: Geriatric population scenario in US 2017 Exhibit 52: Vendor landscape Exhibit 53: Landscape disruption Exhibit 54: Vendors covered Exhibit 55: Vendor classification Exhibit 56: Market positioning of vendors Exhibit 57: AstraZeneca Plc - Vendor overview Exhibit 58: AstraZeneca Plc - Product segments Exhibit 59: AstraZeneca Plc - Organizational developments Exhibit 60: AstraZeneca Plc - Geographic focus Exhibit 61: AstraZeneca Plc - Key offerings Exhibit 62: AstraZeneca Plc - Key customers Exhibit 63: Bayer AG - Vendor overview Exhibit 64: Bayer AG - Product segments Exhibit 65: Bayer AG - Organizational developments Exhibit 66: Bayer AG - Geographic focus Exhibit 67: Bayer AG - Segment focus Exhibit 68: Bayer AG - Key offerings Exhibit 69: Bayer AG - Key customers Exhibit 70: Johnson & Johnson Service, Inc. - Vendor overview Exhibit 71: Johnson & Johnson Services, Inc. - Business segments Exhibit 72: Johnson & Johnson Services, Inc. - Organizational developments Exhibit 73: Johnson & Johnson Services, Inc. - Geographic focus Exhibit 74: Johnson & Johnson Services, Inc. - Segment focus Exhibit 75: Johnson & Johnson Services, Inc. - Key offerings Exhibit 76: Johnson & Johnson Services, Inc. - Key customers Exhibit 77: Pfizer Inc. - Vendor overview Exhibit 78: Pfizer Inc. - Business segments Exhibit 79: Pfizer Inc. - Organizational developments Exhibit 80: Pfizer Inc. - Geographic focus Exhibit 81: Pfizer Inc. - Segment focus Exhibit 82: Pfizer Inc. - Key offerings Exhibit 83: Pfizer Inc. - Key customers Exhibit 84: Takeda Pharmaceutical Co. Ltd. - Vendor overview Exhibit 85: Takeda Pharmaceutical Co. Ltd. - Business segments Exhibit 86: Takeda Pharmaceutical Co. Ltd. - Organizational developments Exhibit 87: Takeda Pharmaceutical Co. Ltd. - Geographic focus Exhibit 88: Takeda Pharmaceutical Co. Ltd. - Key offerings Exhibit 89: Takeda Pharmaceutical Co. Ltd. - Key customers Exhibit 90: Validation techniques employed for market sizing Exhibit 91: Definition of market positioning of vendors

AstraZeneca Plc Bayer AG Johnson & Johnson Services Inc. Pfizer Inc. Takeda Pharmaceutical Co. Ltd.